Sugi Predict

Sugi Predict / Compounds / SCHEMBL392092

SCHEMBL392092

SCHEMBL392092

COC(=O)C1(NC(=O)OC(C)(C)C)CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.44

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ EPHX2 P34913 1/20 0.44
▸ EPHX1 P07099 1/20 0.40
▸ PKM P14618 1/20 0.39
▸ GPR119 Q8TDV5 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ TSHR P16473 2/20 0.38
▸ ALOX15 P16050 1/20 0.38
▸ ATM Q13315 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ RECQL P46063 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21777942 0.92 EPHX2 (0.39) USP2SMN1; SMN2EPHX2EPHX1PKM
SCHEMBL1282312 0.88 PPIA (0.34) USP2SMN1; SMN2EPHX2TSHRALOX15
SCHEMBL2866972 0.88 CYP4F2 (0.40) USP2SMN1; SMN2EPHX2ALDH1A1
SCHEMBL10194444 0.87 EPHX2 (0.34) USP2SMN1; SMN2EPHX2EPHX1PKM
SCHEMBL391708 0.87 USP2 (0.45) USP2SMN1; SMN2EPHX2EPHX1PKM
SCHEMBL1003450 0.85 USP2 (0.44) USP2SMN1; SMN2EPHX2EPHX1GPR119
SCHEMBL22666898 0.85 EPHX2 (0.40) USP2SMN1; SMN2EPHX2EPHX1HPGD
SCHEMBL22962352 0.85 ALDH1A1 (0.36) EPHX2PKMTSHRALDH1A1
SCHEMBL1820679 0.84 MAPT (0.39) ALDH1A1
SCHEMBL21219355 0.84 EPHX2 (0.37) USP2SMN1; SMN2EPHX2EPHX1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12252495-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2025-03-18 — — US disclosed
US-20240109902-A1 PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2024-04-04 — — US disclosed
US-11760760-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2023-09-19 — — US disclosed
US-11760760-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2023-09-19 — — US disclosed
US-20220220116-A1 PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2022-07-14 — — US disclosed
US-20220220116-A1 PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2022-07-14 — — US disclosed
US-11236095-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2022-02-01 — — US disclosed
US-11236095-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2022-02-01 — — US disclosed
US-20200239483-A1 PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2020-07-30 — — US disclosed
US-20200239483-A1 PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2020-07-30 — — US disclosed
EP-2201012-B1 PYRROLO[2,3-D]PYRIMIDIN DERIVATIVES AS PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2014-06-25 — — EP disclosed
US-20120190679-A1 Novel Protein Kinase B Inhibitors - 060 ASTRAZENECA AB (SE) 2012-07-26 — — US disclosed
US-20120190679-A1 Novel Protein Kinase B Inhibitors - 060 ASTRAZENECA AB (SE) 2012-07-26 — — US disclosed
US-8101623-B2 Substituted pyrrolo[2,3-d]pyrimidine as a protein kinase B inhibitor ASTRAZENECA AB (SE) 2012-01-24 — — US disclosed
US-8101623-B2 Substituted pyrrolo[2,3-d]pyrimidine as a protein kinase B inhibitor ASTRAZENECA AB (SE) 2012-01-24 — — US disclosed
EP-2201012-A1 PYRROLO [2, 3 -D] PYRIMIDIN DERIVATIVES AS PROTEIN KINASE B INHIBITORS AstraZeneca AB (SE) 2010-06-30 — — EP disclosed
US-20090163524-A1 Novel Protein Kinase B Inhibitors - 060 ASTRAZENECA AB (SE) 2009-06-25 — — US disclosed
US-20090163524-A1 Novel Protein Kinase B Inhibitors - 060 ASTRAZENECA AB (SE) 2009-06-25 — — US disclosed
WO-2009047563-A1 PYRROLO [2, 3 -D] PYRIMIDIN DERIVATIVES AS PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2009-04-16 — — WO disclosed
WO-2009047563-A1 PYRROLO [2, 3 -D] PYRIMIDIN DERIVATIVES AS PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2009-04-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12252495-B2 Protein kinase B inhibitors PRKAR2B, PRKCB, AKT1 USP2 3329/4885SMN1; SMN2 2587/4885EPHX2 3373/4885
US-20220220116-A1 PROTEIN KINASE B INHIBITORS PRKAR2B, PRKCB, AKT1 USP2 3329/4885SMN1; SMN2 2587/4885EPHX2 3373/4885
US-20240109902-A1 PROTEIN KINASE B INHIBITORS PRKAR2B, PRKCB, AKT1 USP2 3329/4885SMN1; SMN2 2587/4885EPHX2 3373/4885
US-20090163524-A1 Novel Protein Kinase B Inhibitors - 060 PRKAR2B, PRKCB, MAP3K20 USP2 3516/4885SMN1; SMN2 2354/4885EPHX2 3726/4885
US-20200239483-A1 PROTEIN KINASE B INHIBITORS PRKAR2B, PRKCB, AKT1 USP2 3329/4885SMN1; SMN2 2587/4885EPHX2 3373/4885
US-20120190679-A1 Novel Protein Kinase B Inhibitors - 060 PRKAR2B, PRKCB, MAP3K20 USP2 3516/4885SMN1; SMN2 2354/4885EPHX2 3726/4885
US-11236095-B2 Protein kinase B inhibitors PRKAR2B, PRKCB, AKT1 USP2 3329/4885SMN1; SMN2 2587/4885EPHX2 3373/4885
US-11760760-B2 Protein kinase B inhibitors PRKAR2B, PRKCB, AKT1 USP2 3329/4885SMN1; SMN2 2587/4885EPHX2 3373/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.